浙江佐力药业股份有限公司 2025 年半年度报告全文 浙江佐力药业股份有限公司 2025 年半年度报告 （公告编号：2025-051） 2025 年 8 月 1 浙江佐力药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人汪涛、主管会计工作负责人叶利及会计机构负责人(会计主管 人员)冷鹤声明：保证本半年度报告中财务报告的真实、准确、完整。 浙江佐力药业股份有限公司 2025 年半年度报告全文 备查文件目录 一、载有法定代表人签名的 2025 年半年度报告文本； 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及未来计划等前瞻性陈述不构成公司对投资者的实质承诺， 敬请投资者及相关人士理解计划、预测和承诺之间的差异。公司已在本报告 第三节"管理层讨论与分析"之"十、公司面临的风险和应对措施"部分， 详细描述了公司经营中可能存在的风险，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本 ...

数据显示，截至2025年7月31日，中证中药指数(930641)前十大权重股分别为云南白药(000538)、片仔癀 (600436)、同仁堂(600085)、东阿阿胶(000423)、华润三九(000999)、白云山(600332)、吉林敖东 (000623)、众生药业(002317)、以岭药业(002603)、佐力药业(300181)，前十大权重股合计占比54.58%。 中药ETF(159647)，场外联接A：016891；联接C：016892；联接I：022881。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 截至2025年8月18日 09:54，中证中药指数(930641)强势上涨1.62%，成分股天士力(600535)上涨8.03%， 新天药业(002873)上涨7.01%，达仁堂(600329)上涨6.07%，众生药业(002317)，康缘药业(600557)等个股 跟涨。中药ETF(159647)上涨1.53%，最新价报1.06元。 东吴证券指出，创新药产业已现拐点：现阶段的中国创新药在政策和研发两端都完成了厚积薄发。政策 端，《全链条支持创新药发展实施方案》在支付端、 ...

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) has demonstrated strong profitability with a cumulative return of 154.14% over three years, despite a generally lackluster performance in the traditional Chinese medicine sector [1] Financial Performance - The company's net profit attributable to shareholders increased from 25.59 million yuan in 2019 to 508 million yuan in 2024 [1] - The gross profit margin for Zhaoli Pharmaceutical has decreased from 71.43% in 2021 to 60.95% currently, a decline of approximately 10 percentage points [7] Key Products - Zhaoli Pharmaceutical specializes in traditional Chinese medicine products, with its flagship product, Wuling Capsule, generating 1.438 billion yuan in revenue in 2024, accounting for 55.79% of total revenue [3] - Wuling Capsule, used for treating insomnia, is a 1 billion yuan-level product with a stable gross profit margin exceeding 80% [4][5] Market Position and Competitive Advantage - Wuling Capsule benefits from unique barriers to entry, including proprietary technology and its inclusion in the National Essential Medicines List, which limits competition and maintains pricing power [3][5] - The company has successfully increased the packaging size of Wuling Capsule to enhance sales and reduce marginal costs [5] Strategic Focus - Zhaoli Pharmaceutical is committed to its core business of traditional Chinese medicine while expanding into the rapidly growing market for traditional Chinese medicine pieces and granules [11] - The company aims to develop its Bailing series products into a 1 billion yuan-level product by 2025, despite facing competition from established players [12] Sales Channels and Growth Strategy - The company is shifting its sales strategy from primarily hospital sales to a more consumer-oriented approach, targeting online retail and chain pharmacies to tap into the broader health market [13]

金融界消息 截至2025年8月13日收盘，佐力药业（300181）报收于20.01元，下跌0.4%，换手率2.59%， 成交量15.62万手，成交金额3.12亿元。 资金流向方面，今日主力资金净流出1030.98万元，占比成交额3.3%。其中，超大单净流出236.23万 元、占成交额0.76%，大单净流出794.75万元、占成交额2.54%，中单净流出流出1182.57万元、占成交 额3.79%，小单净流入2213.55万元、占成交额7.09%。 佐力药业最新一期业绩显示，截至2025一季报，公司营业总收入8.24亿元、同比增长22.52%，归属净利 润1.81亿元，同比增长27.20%，扣非净利润1.81亿元，同比增长26.16%，流动比率2.011、速动比率 1.619、资产负债率30.38%。 天眼查商业履历信息显示，浙江佐力药业股份有限公司，成立于2000年，位于湖州市，是一家以从事医 药制造业为主的企业。企业注册资本70138.7335万人民币，实缴资本70138.7335万人民币。公司法定代 表人为汪涛。 通过天眼查大数据分析，浙江佐力药业股份有限公司共对外投资了10家企业，参与招投标项目4955 ...

江海证券指出，中药饮片标注保质期使得产品信息更加透明，有助于消费者更好地判断产品质量与安全 性，从而增强对中药饮片的消费信心。消费者在购买时会倾向于选择那些保质期标注清晰、生产企业信 誉良好的产品，这将促使企业更加注重品牌建设与产品质量宣传。随着消费者对中药饮片认知的加深， 一些原本对中药饮片质量存在疑虑的潜在消费者可能会开始尝试购买，从而有望拓展中药饮片的消费市 场。企业可以借此机会，加大产品研发与创新力度，推出更多符合消费者需求的中药饮片产品，如小包 装、便于储存与服用的新型中药饮片剂型。 从资金净流入方面来看，中药ETF近5天获得连续资金净流入，合计"吸金"3002.74万元。截至8月12日， 中药ETF8月以来资金净流入2214.84万。 数据显示，截至2025年7月31日，中证中药指数(930641)前十大权重股分别为云南白药(000538)、片仔癀 (600436)、同仁堂(600085)、东阿阿胶(000423)、华润三九(000999)、白云山(600332)、吉林敖东 (000623)、众生药业(002317)、以岭药业(002603)、佐力药业(300181)，前十大权重股合计占比54.5 ...

金融界8月4日消息，上证指数低开高走，中证1000医药卫生指数 (1000医药，H30444)报13651.50点。 从指数持仓来看，中证1000医药卫生指数十大权重分别为：博瑞医药（3.51%）、通化金马 （2.65%）、泽璟制药（2.51%）、众生药业（1.75%）、昭衍新药（1.7%）、安科生物（1.66%）、一 品红（1.63%）、佐力药业（1.59%）、福瑞股份（1.39%）、东诚药业（1.33%）。 从中证1000医药卫生指数持仓的市场板块来看，上海证券交易所占比55.62%、深圳证券交易所占比 44.38%。 从中证1000医药卫生指数持仓样本的行业来看，化学药占比36.28%、医疗器械占比19.30%、中药占比 17.00%、生物药品占比14.30%、医疗商业与服务占比7.16%、制药与生物科技服务占比5.94%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收 购、合并、分拆等情形的处理，参照计算与维护细则处理。当中证1000指数调整样本时，中证1000行 ...

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The Chinese medicine sector saw a 3.12% increase last week, with the overall pharmaceutical sector rising by 2.95% [2] - The PE (ttm) for the Chinese medicine sector is 29.58X, up 0.89X week-on-week, while the PB (lf) is 2.45X, up 0.08X week-on-week [3] - The "Thousand-Year Herbal" initiative aims to establish a comprehensive communication system for the entire lifecycle of Chinese medicine, focusing on resource protection, quality control, and technological innovation [5] - The recent implementation of centralized procurement for Chinese medicine pieces is expected to drive industry standardization and enhance competitive advantages for companies with strong management and innovation capabilities [6] Market Performance - The Chinese medicine II index closed at 6845.97 points, reflecting a 3.12% increase, while the chemical pharmaceuticals index rose by 5.01% [2][14] - The performance of leading companies includes Qizheng Tibetan Medicine and Zhongsheng Pharmaceutical, while companies like Qidi Pharmaceutical and Kangmei Pharmaceutical lagged behind [2] Valuation - The Chinese medicine sector's PE (ttm) is at 29.58X, which is at the 35.13% percentile since 2013, while the PB (lf) is at 2.45X, at the 8.52% percentile since 2013 [3] Supply Chain Insights - The market for Chinese medicinal materials is currently balanced, with the price index remaining stable despite fluctuations in supply due to extreme weather [4] Investment Suggestions - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Companies with strong R&D capabilities and unique products are recommended, along with those less affected by centralized procurement [12]

金融界消息 截至2025年8月1日收盘，佐力药业（300181）报收于18.94元，上涨1.12%，换手率4.8%， 成交量28.93万手，成交金额5.55亿元。 资金流向方面，今日主力资金净流入2773.59万元，占比成交额5.0%。其中，超大单净流入1915.44万 元、占成交额3.45%，大单净流入858.14万元、占成交额1.55%，中单净流出流入991.49万元、占成交额 1.79%，小单净流出3765.07万元、占成交额6.79%。 天眼查商业履历信息显示，浙江佐力药业股份有限公司，成立于2000年，位于湖州市，是一家以从事医 药制造业为主的企业。企业注册资本70138.7335万人民币，实缴资本70138.7335万人民币。公司法定代 表人为汪涛。 通过天眼查大数据分析，浙江佐力药业股份有限公司共对外投资了10家企业，参与招投标项目4947次， 知识产权方面有商标信息100条，专利信息33条，此外企业还拥有行政许可163个。 来源：金融界 佐力药业最新一期业绩显示，截至2025一季报，公司营业总收入8.24亿元、同比增长22.52%，归属净利 润1.81亿元，同比增长27.20%，扣非净利润1. ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]